R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, 2017. CA Cancer J Clin, 2017.

A. Midha, S. Dearden, and . Mccormack, EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII), American Journal of Cancer Research. e-Century Publishing Corporation, vol.5, issue.9, pp.2892-911, 2015.

F. Janku, D. J. Stewart, and R. Kurzrock, Targeted therapy in non-small-cell lung cancer--is it becoming a reality?, Nat Rev Clin Oncol, vol.7, issue.7, pp.401-415, 2010.

C. Lazzari, A. Bulotta, M. Ducceschi, M. G. Viganò, E. Brioschi et al.,

, Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer, Frontiers in Medicine. Frontiers Media S.A, vol.4, p.4, 2017.

S. Farkona, E. P. Diamandis, and I. M. Blasutig, Cancer immunotherapy: the beginning of the end of cancer, BMC Med. London: BioMed Central, vol.14, p.73, 2016.

C. G. Drake, E. J. Lipson, and J. R. Brahmer, Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer, Nat Rev Clin Oncol, vol.11, issue.1, pp.24-37, 2014.

S. L. Topalian, J. M. Taube, R. A. Anders, and D. M. Pardoll, Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy, Nat Rev Cancer, vol.16, issue.5, pp.275-87, 2016.

W. Wang, R. Lau, D. Yu, W. Zhu, A. Korman et al., PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells, Int Immunol, vol.21, 2009.

M. Duruisseaux, C. Lize-dufranc, C. Badoual, and F. Bibeau, Biomarqueurs prédictifs de l'efficacité des inhibiteurs de checkpoint immunitaire dans le traitement des cancers, Immunothérapie et cancer, vol.5239, issue.1, p.1

J. Brahmer, K. L. Reckamp, P. Baas, L. Crino, W. E. Eberhardt et al.,

, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, vol.373, 2015.

A. Rittmeyer, F. Barlesi, D. Waterkamp, K. Park, F. Ciardiello et al., Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, vol.389, pp.255-65, 2017.

R. S. Herbst, P. Baas, D. Kim, E. Felip, J. L. Pérez-gracia et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, vol.387, pp.1540-50, 2016.

M. Reck, D. Rodríguez-abreu, A. G. Robinson, R. Hui, T. Cs?szi et al., Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, vol.375, 2016.

C. J. Langer, S. M. Gadgeel, H. Borghaei, V. A. Papadimitrakopoulou, A. Patnaik et al., Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. The Lancet Oncology, vol.17, pp.1497-508, 2016.

M. Burotto, A. Thomas, D. Subramaniam, G. Giaccone, and A. Rajan, Biomarkers in Early-Stage Non-Small Cell Lung Cancer: Current Concepts and Future Directions, J Thorac Oncol, vol.9, issue.11, pp.1609-1626, 2014.

M. Ilie, V. Hofman, M. Dietel, J. Soria, and P. Hofman, Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch, vol.468, pp.511-536, 2016.

F. R. Hirsch, A. Mcelhinny, D. Stanforth, J. Ranger-moore, M. Jansson et al., PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project, J Thorac Oncol, vol.12, issue.2, pp.208-230, 2017.

D. L. Rimm, G. Han, J. M. Taube, E. S. Yi, J. A. Bridge et al., , p.24

. Multi, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer, JAMA Oncol

P. Hofman, PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted? Expert Review of Molecular Diagnostics

&. Taylor and . Francis, , vol.17, pp.1097-108, 2017.

D. Planchard, T. Yokoi, M. J. Mccleod, J. R. Fischer, Y. C. Kim et al., A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study, Clin Lung Cancer, vol.17, 2016.

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versus docetaxel in advanced non-squamous non-small-cell lung cancer, N Engl J Med, vol.373, 2015.

O. Abdel-rahman, Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis, Critical Reviews in Oncology/Hematology, vol.101, pp.75-85, 2016.

N. Hart, First EQA Results for PD-L1, pp.1-15, 2017.

M. Tsao and . Iaslc, Atlas of PD-L1 immunohistochemistry testing in lung cancer

M. Tsao, K. M. Kerr, S. Dacic, Y. Yatabe, and F. R. Hirsch, , 2017.

P. Hofman, M. Ilie, S. Lassalle, E. Long, C. Bence et al.,

, Immunohistochimie PD-1/PD-L1 en oncologie thoracique : où en sommesnous ?, Immunothérapie et cancer, vol.5239, issue.1, p.1

J. Adam, I. Rouquette, D. Damotte, C. Badoual, C. Danel et al., 04: Multicentric French Harmonization Study for PD-L1 IHC Testing in NSCLC, Journal of Thoracic Oncology, vol.12, issue.1, 2017.

S. Lantuejoul, J. Adam, N. Girard, M. Duruisseaux, A. Mansuet-lupo et al., Tests immunohistochimiques PD-L1 dans les cancers du poumon non à petites cellules : recommandations par le groupe PATTERN de pathologistes thoraciques, Immunothérapie et cancer, vol.38, issue.2, pp.110-135, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01927078

J. Adam, L. Stang, N. Rouquette, I. Cazes, A. Badoual et al., Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer, Annals of Oncology, vol.29, issue.4, pp.953-961, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01926681

K. M. Mahoney, H. Sun, X. Liao, P. Hua, M. Callea et al., Antibodies to the cytoplasmic domain of PD-L1 most clearly delineate cell membranes in immunohistochemical staining, Cancer Immunology Research, vol.3, issue.12, pp.1308-1323, 2015.

E. R. Parra, P. Villalobos, B. Mino, and J. Rodriguez-canales, Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma, Applied Immunohistochemistry & Molecular Morphology, vol.26, issue.2, p.83, 2018.

E. Paulsen, T. K. Kilvaer, M. R. Khanehkenari, S. Al-saad, S. M. Hald et al., Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach, Clinical Lung Cancer, vol.18, issue.2, pp.220-228, 2017.

M. Ilie, S. Khambata-ford, C. Copie-bergman, L. Huang, J. Juco et al., Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms, vol.12, p.183023, 2017.

E. B. Garon, N. A. Rizvi, R. Hui, N. Leighl, A. S. Balmanoukian et al., Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer, N Engl J Med. Massachusetts Medical Society, vol.372, issue.21, pp.2018-2046, 2015.

D. Santerre, Expression de la protéine PD-L1 par immunohistochimie dans le cancer du poumon non à petites cellules, pp.1-53, 2017.

A. Gagné, W. Enlow, M. Pigeon, M. Orain, S. Turcotte et al., Comprehensive Assessment of PD-L1 Staining Heterogeneity in Pulmonary 26

, Adenocarcinomas Using Tissue Microarrays: Impact of the Architecture Pattern and the Number of Cores, The American Journal of Surgical Pathology

A. Bellesoeur, Biomarqueurs des immunothérapies anti-PD-1/PD-L1: facteurs cliniques, histologiques et immunohistochimiques associés au statut PD-L1, pp.1-75, 2016.

J. Mclaughlin, G. Han, K. A. Schalper, D. Carvajal-hausdorf, V. Pelekanou et al., Quantitative assessment of the heterogeneity of PD-L1 expression in nonsmall-cell lung cancer, JAMA Oncol, vol.1, 2016.

V. Velcheti, K. A. Schalper, D. E. Carvajal, V. K. Anagnostou, K. N. Syrigos et al., Programmed death ligand-1 expression in non-small cell lung cancer, Lab Invest. United States & Canadian Academy of Pathology, vol.94, issue.1, pp.107-123, 2013.

M. Ilie, E. Long-mira, C. Bence, C. Butori, S. Lassalle et al., Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies, Annals of Oncology, vol.27, issue.1, pp.147-53, 2015.

S. Kitazono, Y. Fujiwara, K. Tsuta, H. Utsumi, S. Kanda et al., Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non Small-Cell Lung Cancer, Clinical Lung Cancer, vol.16, issue.5, pp.385-90, 2015.

A. H. Scheel, G. Baenfer, G. Baretton, M. Dietel, R. Diezko et al., Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer, Histopathology, vol.72, issue.3, pp.449-59, 2018.

D. Casadevall, S. Clavé, Á. Taus, M. Hardy-werbin, P. Rocha et al., Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples, Clinical Lung Cancer, vol.18, issue.6, p.682, 2017.
DOI : 10.1016/j.cllc.2017.04.014

A. H. Scheel, M. Dietel, L. C. Heukamp, K. Johrens, T. Kirchner et al., Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas, Mod Pathol. United States & Canadian Academy of Pathology, vol.29, issue.10, pp.1165-72, 2016.
DOI : 10.1038/modpathol.2016.117

URL : https://www.nature.com/articles/modpathol2016117.pdf

P. Gaule, J. W. Smithy, M. Toki, J. Rehman, F. Patell-socha et al., A Quantitative Comparison of Antibodies to PD-L1, JAMA Oncol, 2016.

S. Hendry, D. J. Byrne, G. M. Wright, R. J. Young, S. Sturrock et al., Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer, Journal of Thoracic Oncology, vol.13, issue.3, pp.367-76, 2018.
DOI : 10.1016/j.jtho.2017.11.112

URL : http://www.jto.org/article/S155608641733054X/pdf

M. Udall, M. Rizzo, J. Kenny, J. Doherty, S. Dahm et al., PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and testvalidation metrics, Diagnostic Pathology, vol.13, issue.1, p.12, 2018.
DOI : 10.1186/s13000-018-0689-9

URL : https://diagnosticpathology.biomedcentral.com/track/pdf/10.1186/s13000-018-0689-9

C. Li, C. Huang, T. S. Mok, W. Zhuang, H. Xu et al., , pp.22-25

. Pd-l1, Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer, Journal of Thoracic Oncology, vol.12, issue.10, pp.1536-1579, 2017.

D. Pinto, G. De-souza-viana, L. , S. Neto, C. et al., Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data, J Immunol Res. Hindawi, issue.11, pp.9839685-9839697, 2016.

G. Botti, G. Scognamiglio, and M. Cantile, PD-L1 Immunohistochemical Detection in Tumor Cells and Tumor Microenvironment: Main Considerations on the Use of

, International Journal of Molecular Sciences, vol.17, issue.7, p.1046, 2016.

G. Scognamiglio, D. Chiara, A. , D. Bonito, M. Tatangelo et al., Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types, International Journal of Molecular Sciences, vol.17, issue.5, 2016.

J. M. Taube, A. Klein, J. R. Brahmer, H. Xu, X. Pan et al., Association of PD-1, PD-1 ligands, and other features of the tumor immune micro-environment with response to anti-PD-1 therapy, Clin Cancer Res, vol.20, 2014.

J. M. Taube, J. Galon, L. M. Sholl, S. J. Rodig, T. R. Cottrell et al., Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol, vol.31, pp.214-248, 2018.

W. J. Howat, A. Lewis, P. Jones, C. Kampf, F. Pontén et al., Antibody validation of immunohistochemistry for biomarker discovery: Recommendations of a consortium of academic and pharmaceutical based histopathology researchers. Advancing the boundaries of molecular cellular pathology, vol.70, pp.34-42, 2014.

J. Bordeaux, A. W. Welsh, S. Agarwal, E. Killiam, M. T. Baquero et al., Antibody validation, BioTechniques, vol.48, issue.3, pp.197-209, 2010.

P. D. Reiss, D. Min, and M. Y. Leung, Working towards a consensus for antibody validation, vol.3, p.266, 1000.
DOI : 10.12688/f1000research.5668.1

URL : https://f1000research.com/articles/3-266/v1/pdf